Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome

Rheumatology
Elena PontariniSalvatore De Vita

Abstract

The aim of this study was to investigate the biological effects of belimumab on B cells in the first phase II open-label trial with belimumab in patients with primary SS (pSS) (BELISS). Peripheral blood B cell subsets and their B cell activating factor-receptor (BAFF-R) expression were analysed by multicolour flow cytometry in 10 pSS patients either before or after 24 and 52 weeks of therapy with belimumab. Serum BAFF levels were analysed by ELISA. At baseline, pSS patients showed a significant increase in circulating B cells compared with healthy donors matched for age and sex, with a predominant expansion of transitional and naive B cell subsets. pSS patients also showed higher serum BAFF levels and lower B cell BAFF-R expression. Therapy with belimumab in pSS patients induced a significant reduction in transitional and naive B cell subsets to levels similar to those observed in healthy donors. Furthermore, belimumab normalized BAFF-R expression in all B subsets comprised within the memory compartment. The restoration of B cell frequency and subset composition in response to belimumab was also associated with a decrease in serum levels of Ig, RF, ANAs, and with an increase in the C4 complement fraction. All of these belimumab...Continue Reading

Associated Clinical Trials

References

May 15, 2002·Annals of the Rheumatic Diseases·C VitaliUNKNOWN European Study Group on Classification Criteria for Sjögren's Syndrome
Jan 15, 2003·Annals of the Rheumatic Diseases·X MarietteR Kimberly
Feb 24, 2006·Rheumatology·M N LazarusD A Isenberg
May 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chungwen WeiIñaki Sanz
Sep 11, 2008·Annals of the Rheumatic Diseases·A BinardJ-O Pers
May 6, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Arumugam PalanichamyJennifer H Anolik
Feb 19, 2011·Current Opinion in Rheumatology·William StohlMichael P Cancro
Nov 30, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Matthias KreuzalerHermann Eibel
Jul 4, 2012·Journal of Autoimmunity·Ayan LahiriJacques-Olivier Pers
Mar 8, 2013·The Journal of Allergy and Clinical Immunology·Kathrin PieperHermann Eibel
Sep 21, 2013·Annual Review of Pathology·Clio P Mavragani, Haralampos M Moutsopoulos
Dec 19, 2013·Annals of the Rheumatic Diseases·Xavier MarietteSalvatore De Vita

❮ Previous
Next ❯

Citations

Oct 31, 2015·Scandinavian Journal of Rheumatology·V FurerD Paran
Nov 29, 2015·Journal of Dermatological Science·Mitsuha HayashiHidemi Nakagawa
Jun 1, 2016·La Presse médicale·Jacques-Olivier Pers, Alain Saraux
Oct 16, 2016·Journal of Clinical Medicine·Julian Lawrence AmbrusAmmon Peck
May 18, 2016·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Ryan L Quock
Jun 5, 2018·Expert Opinion on Drug Discovery·Yaxi Li, Tianfu Wu
Jul 4, 2015·Arthritis Research & Therapy·Naomi I MariaMarjan A Versnel
Jun 24, 2017·Journal of Ophthalmology·Hua WangQiang-Xiang Li
Jan 19, 2017·Annual Review of Medicine·Clio P Mavragani
Jun 9, 2020·Clinical and Experimental Medicine·F J Carrillo-BallesterosEdith Oregon-Romero
Feb 2, 2018·Therapeutic Advances in Musculoskeletal Disease·Nicoletta Del Papa, Claudio Vitali
Feb 26, 2019·Frontiers in Immunology·Smita Y PatelStephen Jolles
Apr 8, 2021·Nature Reviews. Rheumatology·Patrick MaschmeyerAndreas Radbruch
Aug 3, 2021·Frontiers in Medicine·Farzana ChowdhuryMichele Bombardieri
Jul 30, 2021·Expert Opinion on Pharmacotherapy·Soledad RetamozoPilar Brito-Zerón

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.